344 related articles for article (PubMed ID: 34009481)
21. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
22. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
23. [Systemic treatment of inoperable metastasized malignant melanoma].
Gutzmer R; Rauschenberg R; Meier F
Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
[TBL] [Abstract][Full Text] [Related]
24. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
25. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma.
Viñal D; Martinez D; Espinosa E
Clin Transl Oncol; 2019 Aug; 21(8):1061-1066. PubMed ID: 30607792
[TBL] [Abstract][Full Text] [Related]
27. Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy.
Myrdal CN; Sundararajan S
Case Rep Oncol Med; 2020; 2020():4392562. PubMed ID: 32670650
[TBL] [Abstract][Full Text] [Related]
28. Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
Rogiers A; Wolter P; Bechter O
Melanoma Res; 2017 Apr; 27(2):164-167. PubMed ID: 28252479
[TBL] [Abstract][Full Text] [Related]
29. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
30. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
[TBL] [Abstract][Full Text] [Related]
31. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
32. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
[TBL] [Abstract][Full Text] [Related]
33. Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2016 Jan; 53():125-34. PubMed ID: 26707829
[TBL] [Abstract][Full Text] [Related]
34. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
35. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
37. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
[TBL] [Abstract][Full Text] [Related]
38. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
39. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
40. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
